keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall cell lung ca

keyword
https://www.readbyqxmd.com/read/28643734/the-significance-of-serum-leptin-level-in-patients-with-early-stage-nonsmall-cell-lung-cancer
#1
Fatih Karatas, Bulent Yalcin, Suleyman Sahin, Hakan Akbulut, Gungor Utkan, Ahmet Demirkazik, Fikri Icli
BACKGROUNDS: The serum leptin level (SLL) has been shown to increase in patients with nonsmall cell lung cancer (NSCLC). However, available data regarding the relation between SLL and tumor subtypes, survival, cachexia, and tumor respectability in NSCLC are still under debate. The aim of this study is to evaluate SLL in NSCLC patients with and without cachexia. MATERIALS AND METHODS: A total of 71 patients with early stage NSCLC were enrolled in this prospective study...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28643733/a-prospective-randomized-controlled-study-of-cisplatin-versus-carboplatin-based-regimen-in-advanced-squamous-nonsmall-cell-lung-cancer
#2
Amr Shafik Saad, Ramy R Ghali, May Ahmed Shawki
BACKGROUND: The use of cisplatin (Cis) versus carboplatin (Carb) in the treatment of advanced nonsmall cell lung cancer (NSCLC) is controversial. The aim of the study was to compare the safety and efficacy of Cis versus Carb in squamous NSCLC. PATIENTS AND METHODS: A prospective, randomized, controlled, open-label study was conducted on advanced squamous NSCLC patients who were randomly assigned to receive Cis (40 mg/m 2 [day 1 and day 8]) or Carb (area under the curve = 5 [day 1]) combined with gemcitabine [Gem] (1000 mg/m 2 [day 1 and day 8]) of a 3-week schedule for six cycles...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28631925/anticancer-activity-of-polyoxometalate-bisphosphonate-complexes-synthesis-characterization-in-vitro-and-in-vivo-results
#3
Amandine Boulmier, Xinxin Feng, Olivier Oms, Pierre Mialane, Eric Rivière, Christopher J Shin, Jiaqi Yao, Tadahiko Kubo, Taisuke Furuta, Eric Oldfield, Anne Dolbecq
We synthesized a series of polyoxometalate-bisphosphonate complexes containing Mo(VI)O6 octahedra, zoledronate, or an N-alkyl (n-C6 or n-C8) zoledronate analogue, and in two cases, Mn as a heterometal. Mo6L2 (L = Zol, ZolC6, ZolC8) and Mo4L2Mn (L = Zol, ZolC8) were characterized by using single-crystal X-ray crystallography and/or IR spectroscopy, elemental and energy dispersive X-ray analysis and (31)P NMR. We found promising activity against human nonsmall cell lung cancer (NCI-H460) cells with IC50 values for growth inhibition of ∼5 μM per bisphosphonate ligand...
June 20, 2017: Inorganic Chemistry
https://www.readbyqxmd.com/read/28628491/calcein-acetoxymethy-ester-enhances-the-antitumor-effects-of-doxorubicin-in-nonsmall-cell-lung-cancer-by-regulating-the-topbp1-p53rr-pathway
#4
Yinxiang Lv, Rongrong Liu, Shangzhi Xie, Xiaoxiao Zheng, Jiayan Mao, Ying Cai, Wei Chen
Calcein acetoxymethyl ester (calcein-AM) treatment has been reported to exert antitumor effects in certain cancer cells; however, the detailed mechanism of action of calcein-AM in cancers remains unclear, especially in nonsmall cell lung cancer (NSCLC). This study focused on the function and mechanism of action of calcein-AM in NSCLC. We used cell viability assays, western blotting, and EdU proliferation assay combined with calcein-AM treatment or siRNA interference to investigate the role of topoisomerase IIβ binding protein 1 (TopBP1) and p53 in NSCLC chemotherapy...
June 16, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28620891/population-pharmacokinetic-modeling-of-olaratumab-an-anti-pdgfr%C3%AE-human-monoclonal-antibody-in-patients-with-advanced-and-or-metastatic-cancer
#5
Gary Mo, John R Baldwin, Debra Luffer-Atlas, Robert L Ilaria, Ilaria Conti, Michael Heathman, Damien M Cronier
BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-α (PDGFRα). In a randomized phase II study, olaratumab plus doxorubicin met its predefined primary endpoint for progression-free survival and achieved a highly significant improvement in overall survival versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma (STS). In this study, we characterize the pharmacokinetics (PKs) of olaratumab in a cancer patient population...
June 15, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28598227/integration-of-a-palliative-care-intervention-into-community-practice-for-lung-cancer-a-study-protocol-and-lessons-learned-with-implementation
#6
Huong Q Nguyen, Thomas Cuyegkeng, Tieu O Phung, Karisa Jahn, Tami Borneman, Mayra Macias, Nora Ruel, Betty Ferrell
BACKGROUND: A notable gap in the evidence base for outpatient palliative care (PC) for cancer is that most trials were conducted in specialized oncology or academic centers with limited translation and further evaluation in "real-world" settings. Health systems are desperate for guidance regarding the most effective and sustainable PC service models. OBJECTIVE: Describe the study protocol to evaluate the dissemination of a previously tested nurse-led PC intervention (PCI) for patients with lung cancer and their family caregiver in community-based settings, lessons learned in adapting and implementing the PCI, and implications for future dissemination-translational efforts Design: Two-group, prospective sequential, quasi-experimental design with Phase 1 (Usual care) followed by Phase 2 (Intervention) setting/subjects...
June 9, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28594473/tpgs-functionalized-polydopamine-modified-mesoporous-silica-as-drug-nanocarriers-for-enhanced-lung-cancer-chemotherapy-against-multidrug-resistance
#7
Wei Cheng, Chaoyu Liang, Lv Xu, Gan Liu, Nansha Gao, Wei Tao, Lingyan Luo, Yixiong Zuo, Xusheng Wang, Xudong Zhang, Xiaowei Zeng, Lin Mei
A nanocarrier system of d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)-functionalized polydopamine-coated mesoporous silica nanoparticles (NPs) is developed for sustainable and pH-responsive delivery of doxorubicin (DOX) as a model drug for the treatment of drug-resistant nonsmall cell lung cancer. Such nanoparticles are of desired particle size, drug loading, and drug release profile. The surface morphology, surface charge, and surface chemical properties are also successfully characterized by a series of techniques such as transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), Brunauer-Emmett-Teller (BET) method, thermal gravimetric analysis (TGA), dynamic light scattering (DLS), and Fourier transform infrared spectroscopy (FTIR)...
June 8, 2017: Small
https://www.readbyqxmd.com/read/28589243/rnai-targeting-stmn-alleviates-the-resistance-to-taxol-and-collectively-contributes-to-down-regulate-the-malignancy-of-nsclc-cells-in-vitro-and-in-vivo
#8
Dan Long, Ting Yu, Xian Chen, Ying Liao, Xuechi Lin
Stathmin (STMN) plays a vital role in maintaining the malignant behavior of cancer through directly regulating microtubule dynamics equilibrium. Taxol, an effective chemotherapeutics mainly acting to promote microtubule polymerization, has been commercially applied in treating solid tumors, which results in serious drug resistance. Our study demonstrated that STMN RNA interference (RNAi) enlarged taxol-induced inhibitions in cellular proliferation, colony formation, and multidimensional spaces of cell immigration and decreased half maximal inhibitory concentration (IC50) of taxol in nonsmall cell lung cancer (NSCLC) NCI-H1299 cells; STMN RNAi and taxol jointly attenuated the expressions of extracellular regulated kinase (ERK), nuclear factor kappa B (NF-κB) and B cell lymphoma-2 (Bcl-2), but up regulated Bax expression and initiated intrinsic cell death pathway by activating caspase-3 and caspase-9, while inhibited interleukin 10 (IL-10) autocrine from cell culture supernatant and xenografted mouse serum, as well as intracellular expressions of IL-10 protein and mRNA in vitro; additionally, neutralizing IL-10 alone would incur cell apoptosis to some degree; the further study confirmed that RNAi targeting STMN promoted the sensitivity of taxol in different NSCLC cells...
June 7, 2017: Cell Biology and Toxicology
https://www.readbyqxmd.com/read/28588841/nasogastric-tube-administered-alectinib-achieved-long-term-survival-in-a-crizotinib-refractory-nonsmall-cell-lung-cancer-patient-with-a-poor-performance-status
#9
Osamu Kanai, Young Hak Kim, Koichi Nakatani, Kohei Fujita, Tadashi Mio
Alectinib shows remarkable efficacy against anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), with minimal adverse effects. Therefore, alectinib may provide a survival benefit to ALK-positive NSCLC patients with a poor performance status. If the medication cannot be taken by mouth, the patient may be given alectinib through a nasogastric tube.
June 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28585617/-immunotherapy-for-lung-cancer
#10
Gyula Ostoros
Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate and immunogenicity. The PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab is a labelled indication in second line setting in advanced nonsmall cell lung cancer (NSCLC). Avelumab and durvalumab have promising activity as well. Based on the data of KEYNOTE 024 trial, pembrolizumab is approved in first line setting for cases with ≥50% PD-L1 expression...
June 6, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28572122/chemotherapy-for-pulmonary-large-cell-neuroendocrine-carcinomas-does-the-regimen-matter
#11
Jules L Derks, Robert Jan van Suylen, Erik Thunnissen, Michael A den Bakker, Harry J Groen, Egbert F Smit, Ronald A Damhuis, Esther C van den Broek, Ernst-Jan M Speel, Anne-Marie C Dingemans
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003-2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as "NSCLC-t", comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; "NSCLC-pt", with pemetrexed treatment only; and "SCLC-t", consisting of etoposide chemotherapy...
June 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28567503/planning-benchmark-study-for-sbrt-of-early-stage-nsclc-results-of-the-degro-working-group-stereotactic-radiotherapy
#12
Christos Moustakis, Oliver Blanck, Fatemeh Ebrahimi Tazehmahalleh, Mark Ka Heng Chan, Iris Ernst, Thomas Krieger, Marciana-Nona Duma, Markus Oechsner, Ute Ganswindt, Christian Heinz, Horst Alheit, Hilbert Blank, Ursula Nestle, Rolf Wiehle, Christine Kornhuber, Christian Ostheimer, Cordula Petersen, Gerhard Pollul, Wolfgang Baus, Georg Altenstein, Eric Beckers, Katrin Jurianz, Florian Sterzing, Matthias Kretschmer, Heinrich Seegenschmiedt, Torsten Maass, Stefan Droege, Ulrich Wolf, Juergen Schoeffler, Uwe Haverkamp, Hans Theodor Eich, Matthias Guckenberger
PURPOSE: The aim was to evaluate stereotactic body radiation therapy (SBRT) treatment planning variability for early stage nonsmall cell lung cancer (NSCLC) with respect to the published guidelines of the Stereotactic Radiotherapy Working Group of the German Society for Radiation Oncology (DEGRO). MATERIALS AND METHODS: Planning computed tomography (CT) scan and the structure sets (planning target volume, PTV; organs at risk, OARs) of 3 patients with early stage NSCLC were sent to 22 radiotherapy departments with SBRT experience: each department was asked to prepare a treatment plan according to the DEGRO guidelines...
May 31, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28562552/plasma-rich-in-growth-factors-for-the-treatment-of-rapidly-progressing-refractory-corneal-melting-due-to-erlotinib-in-nonsmall-cell-lung-cancer
#13
Adriano Guarnieri, Belén Alfonso-Bartolozzi, Gianfranco Ciufo, Javier Moreno-Montañés, Ignacio Gil-Bazo
RATIONALE: Erlotinib, an antineoplastic agent, is indicated for the treatment of patients with advanced nonsmall cell lung cancer. Most common adverse events are manageable, although more severe ones require dose reduction or discontinuation of erlotinib treatment. PATIENT CONCERNS: We present a case of severe corneal ulcer treated with autologous plasma rich in growth factors. DIAGNOSES: A 76-year-old woman with stage IVB (cT2a N0 M1c) lung cancer under erlotinib treatment presented with rapidly progressing corneal ulcer...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28560238/high-pd-1-expression-on-regulatory-and-effector-t-cells-in-lung-cancer-draining-lymph-nodes
#14
Rieneke van de Ven, Anna-Larissa N Niemeijer, Anita G M Stam, Sayed M S Hashemi, Christian G Slockers, Johannes M Daniels, Erik Thunnissen, Egbert F Smit, Tanja D de Gruijl, Adrianus J de Langen
The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (IHC) that will identify patients likely to benefit from this therapy. In this exploratory study we assessed the differences in T-cell subsets and PD-1 expression levels on T-cells in tumour-draining lymph nodes (TDLNs) and peripheral blood mononuclear cells (PBMCs)...
April 2017: ERJ Open Research
https://www.readbyqxmd.com/read/28535543/microrna-181a-5p-impedes-il-17-induced-nonsmall-cell-lung-cancer-proliferation-and-migration-through-targeting-vcam-1
#15
Yang Cao, Dan Zhao, Ping Li, Lanrong Wang, Bingli Qiao, Xiaoyan Qin, Lei Li, Yang Wang
AIM: The contribution of the inflammatory mediator interleukin-17 (IL-17) in nonsmall cell lung cancer (NSCLC) malignancy has been reported in the literature. MicroRNA-181a-5p (miR-181a-5p) acts as a tumor suppressor which can regulate target gene at the posttranscriptional level. Our study aimed to investigate the interaction between IL-17 and miR-181a-5p in NSCLC. METHODS: 35 patients with NSCLC and 24 COPD controls were selected and examined in our study. In vitro, H226 and H460 cell lines were exposed to different doses (20, 40, 60, and 80 ng/mL) of IL-17 to examine the effect of IL-17 on miR-181a-5p and vascular cell adhesion molecule 1 (VCAM-1) expression...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28514730/circulating-micrornas-as-novel-biomarkers-of-alk-positive-nonsmall-cell-lung-cancer-and-predictors-of-response-to-crizotinib-therapy
#16
Liang-Liang Li, Li-Li Qu, Han-Jiang Fu, Xiao-Fei Zheng, Chuan-Hao Tang, Xiao-Yan Li, Jian Chen, Wei-Xia Wang, Shao-Xing Yang, Lin Wang, Guan-Hua Zhao, Pan-Pan Lv, Min Zhang, Yang-Yang Lei, Hai-Feng Qin, Hong Wang, Hong-Jun Gao, Xiao-Qing Liu
Circulating microRNAs are potential diagnostic and predictive biomarkers, but have not been investigated for patients with anaplastic lymphoma kinase (ALK)-positive lung cancer. In this exploratory study, we sought to identify potential plasma biomarkers for ALK-positive non-small cell lung cancer (NSCLC). A microRNA microarray was used to select ALK-related microRNAs in ALK-positive NSCLC (n = 3), ALK-negative NSCLC (n = 3), and healthy subjects (n = 3). Plasma levels of 21 microRNAs were differentially expressed for ALK-positive and ALK-negative NSCLC, including 14 down-regulated and 7 up-regulated microRNAs...
April 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28514208/clinical-significance-and-tumor-suppressive-function-of-mir-516b-in-nonsmall-cell-lung-cancer
#17
Junfei Zhu, Youlin Zhang, Xi Yang, Litong Jin
BACKGROUND: MicroRNA-516b (miR-516b) has been recently reported to be downregulated in nonsmall cell lung cancer (NSCLC). However, its clinical significance and biological function in NSCLC remain to be clarified. MATERIALS AND METHODS: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of miR-516b in 82 paired fresh primary tumor tissues and NSCLC cell lines. The association of miR-516b expression with clinicopathological factors and prognosis was statistically analyzed by SPSS 21...
May 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28511796/attenuation-of-deregulated-mir-369-3p-expression-sensitizes-non-small-cell-lung-cancer-cells-to-cisplatin-via-modulation-of-the-nucleotide-sugar-transporter-slc35f5
#18
Guang-Jun Hao, Yan-Hui Ding, Hui Wen, Xiao-Feng Li, Wei Zhang, Hu-Yan Su, Dong-Mei Liu, Nian-Lin Xie
Deregulation of the microRNAs (miRNAs), a cluster of important posttranscriptional regulators, has been frequently associated with lung cancer (LCa). However, the emerging mechanism for how miRNAs is linked causally in the development of LCa chemoresistance is poorly understood. Herein, we established for the time the up-regulation of miR-369-3p in cisplatin (DDP)-resistant nonsmall cell lung cancer (NSCLC) tissues and cells. Its deregulation was found to be correlated to the magnitude of malignancy in well-characterized LCa cells...
May 13, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28508826/genomic-aberrations-in-non-small-cell-lung-cancer-and-their-impact-on-treatment-outcome
#19
REVIEW
Amrallah A Mohammed, Hani El-Tanni, Mohammed A Alsakkaf, Ahmad A Mirza, Tariq Al-Malki Atiah, Arwa Al-Malki Atiah
The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC...
January 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28504995/remote-ischemic-preconditioning-decreases-oxidative-lung-damage-after-pulmonary-lobectomy-a-single-center-randomized-double-blind-controlled-trial
#20
José García-de-la-Asunción, Laura Bruno, Jaume Perez-Griera, Genaro Galan, Alfonso Morcillo, Richard Wins, Eva García-Del-Olmo, Ricardo Guijarro, Benjamín Sarriá, Francisco Martí, Marina Soro, Francisco Javier Belda
BACKGROUND: During lobectomy in patients with lung cancer, the operated lung is often -collapsed and hypoperfused. Ischemia/reperfusion injury may then occur when the lung is -re-expanded. We hypothesized that remote ischemic preconditioning (RIPC) would decrease oxidative lung damage and improve gas exchange in the postoperative period. METHODS: We conducted a single-center, randomized, double-blind trial in patients with nonsmall cell lung cancer undergoing elective lung lobectomy...
May 11, 2017: Anesthesia and Analgesia
keyword
keyword
13799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"